Insulin resistance

Year 2015, Volume: 7 Issue: 2, 1 - 5, 01.08.2015

Eşref M. Özer

Abstract

Insulin resistance is a state in which a given concentration of insulin produces a less-than-expected biological effect. Insulin resistance is defined as the requirement of high dose insulin to attain glycemic control and to prevent ketosis. The syndromes of insulin resistance present a clinical spectrum which includes obesity, glucose intolerance, type 2 diabetes and the metabolic syndrome, as well as an extreme insulin-resistant state.

Keywords

insulin resistance, obesity, type 2 diabetes, metabolic syndrome

İnsülin direnci

Abstract

İnsülin direnci, insülinin beklenen biyolojik etkisinden daha azını gösterme halidir. İnsülin direnci, glisemik kontrol ve ketozu önlemek için daha yüksek dozlarda insülin konsantrasyonuna ihtiyaç gösterir. İnsülin sendromları, klinikte kendisini obezite, bozulmuş glukoz toleransı, tip 2 diyabet, metabolik sendrom ve ciddi insülin direnci sendromları ile gösterir.

Keywords

insülin direnci, obezite, tip 2 diyabet, metabolik sendrom

References

• Ahren B, Pacini G. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes Obes Metab 2005; 7(1): 2-8.
• Mari A, Ahren B, Pacini G. Assessment of in- sulin secretion in relation to insulin resistance. Curr Opin Clin Nutr Metab care 2005; 8(5): 529-533.
• Reaven GM. Pathophsiology of insulin resist- ance in human disease. Physiol Rev. 1995; 75(3): 473-486.
• Kim JA, Wei Y, Sowers JR. Role of mitochon- drial dysfunction in insulin resistance. Circ Res 2008; 102(4): 401-414.
• Lee SH, Park SA, Ko SH et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascu- lar disease in type 2 diabetes mellitus patients. Metabolism 2010; 59(2): 241-246.
• Klok MD, Jakopsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007; 8(1): 21-34.
• Reaven G, Abbasi F, McLaughin T. Obesity, insulin resistance and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223.
• Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008; 14(3-4): 222-231.
• Florez H, Castillo-Florez S, Mendez A et al. C-reactive protein is elavated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006; 71(1): 92-100.
• Rifai N. High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome. Clin Chem. 2005; 51(3): 504-505.
• Semple RK, Cochran EK, Soos MA et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin re- sistance. Diabetes Care. 2008; 31(5): 977-979.
• Moreno-Navarrete JM, Catalan V, Ortega F et al. Circulating omentin concentration increases after weight loss. Nutr Metab. 2010; 7: 27-36.
• Diamant M, Tushuizen ME. The metabolic syn- drome and endothelialdysfunction: common highway to type 2 diabetes and cardiovascular disease. Curr Diab Rep 2006; 6(4): 279-286.
• Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the metabolic syn- drome: the Atherosclerosis Risk in Communi- ties Study. Circulation. 2008; 117(6): 754-761.
• Van Raalte DH, Brands M, Van der Zijl NJ et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011; 54(8): 2103-2112.
• Baudrand R, Campino C, Carvajal CA et al. High sodium intake is associated with in- creased glucocorticoid production, insulin resistance and metabolic syndrome. Clin Endo- crinol 2014; 80(5): 677-684.
• DE Wit S, Sabin Ca, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetetes Care 2008; 31(6): 1224- 1229.
• Yu IC, Lin HY, Sparks JD et al. Androgenrecep- tor roles in insulin resistance and obesity in males: the linkagee of androgen-deprivation therapy to metabolic syndrome. Diabetes 2014; 63(10): 3180-3188.
• Sarti C, Gallagher J. The metabolic syndrome prevalance, CHD risk and treatment. J Diabetes Complications 2006; 20(2): 121-132.
• Levy- Marchal C, Arslanian S, Cutfield W et al.Insulin resistance in children: consensus, perspective and future directions. J Clin Endo- crinol Metab 2010; 95(12): 5189-5198.
• Kahn R, Buse J, Ferrannini E et al. The metabol- ic syndrome: time for a critical appraisal: joint statement from the American Diabetes Asso- ciation and the European Association fort he Study of Diabetes. Diabetes Care. 2005; 28(9): 2289-2304.
• Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006; 29(3): 270-280.
• De Taeye B, Smith LH, Vaughan DE. Plasmino- gen activator inhibitor-1: a common denom- inator in obesity, diabetes and cardiovascular disease. Curr OPin Pharmacol 2005; 5(2): 149-154.
• Sjöholm A, Nyström T. Endothelial inflamma- tion in insulin resistance. Lancet. 2005; 365 (9459): 610-612.
• Matthews DR, Hosker JP, Rudenski AS et al. Ho- meostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412-419.
• Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accu- rate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2008; 249(1): 15-26.
• Muniyappa R, Lee S, Chen H et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294(1): 15-26.
• Jensterle M, Janez A, Mlinar B et al.Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol 2008; 158(6): 793-801.
• Salpeter SR, Buckley NS, Kahn JA et al. Me- ta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008; 121(2): 149-157.
• Quinn CE, Hamilton PK, Lockhart CJ et al. Thi- azolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 2008; 153(4): 636-645.
• Lee WJ, Lee YC, Ser KH et al. Improvement of insulin resistance after obesity surgery: a com- parison of gastric banding and bypass proce- dures. Obes Surg 2008; 18(9): 1119-1125.
• Herman WH, Hoerger TJ, Brandle M et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005; 142(5): 323-332.
• Hawley JA, Lessard SJ. Exercise training-in- duced improvements in insulin action. Acta Physiol 2008; 192(1): 127-135.